Patient Who Had No Luck With GLP-1 Drugs Found Success With Surgery
This is a MedPage Today story. This story is part of a series called "Ozempic: Weighing the Risks and Benefits." It was produced in part through a grant from the NIHCM Foundation. This is a sidebar to a story on how bariatric surgeons are being put out of work as a result of the rise in GLP-1 drugs. For the main story, click here. Sandra Sio weighed 300 pounds and couldn't diet it away. For years she tried with no luck. The 35-year-old San Diego-area dental office manager and single mother of two said she went to her doctor in 2022 asking for bariatric surgery. She wanted the extra pounds gone. Instead, he convinced her to try injections of semaglutide (Wegovy), one of the newer GLP-1 receptor agonists prescribed for weight loss that have received so much media attention and praise for their ability to suppress appetite and slow digestion. But the weekly injections didn't work for her. "I was just very nauseous and sick. I would wake up nauseous and go to bed nauseous and be...
What's Your Reaction?